Masumi Ueda Oshima
Overview
Explore the profile of Masumi Ueda Oshima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levis M, Hamadani M, Logan B, Jones R, Singh A, Litzow M, et al.
Blood
. 2025 Jan;
PMID: 39775763
BMT CTN 1506 ("MORPHO"; NCT02997202) was a randomized phase 3 study of gilteritinib compared to placebo as maintenance therapy after hematopoietic stem cell transplantation (HCT) for patients with FLT3-ITD-mutated acute...
2.
Sanchez E, Krantz E, Kassamali Escobar Z, Tverdek F, Rosen E, Ueda Oshima M, et al.
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae570.
PMID: 39450393
Background: There are limited data on the contemporary epidemiology of recurrent infection (CDI) among hematopoietic cell transplant (HCT) recipients. We aimed to determine the incidence, risk factors, and outcomes for...
3.
Ueda Oshima M, Higgins J, Jenkins I, Randolph T, Smith T, Valentine 3rd C, et al.
Sci Transl Med
. 2024 Oct;
16(770):eado5108.
PMID: 39441907
After allogeneic hematopoietic cell transplantation (HCT), a very small number of donor stem cells reconstitute the recipient hematopoietic system, whereas the donor is left with a near-normal pool of stem...
4.
Wickline M, Carpenter P, Harris J, Iribarren S, Reding K, Pike K, et al.
Vaccine
. 2024 Oct;
42(26):126374.
PMID: 39437647
Revaccination to restore immunity to vaccine-preventable diseases (VPDs) is essential risk mitigation in the prevention of infectious morbidity and mortality after hematopoietic cell transplantation (HCT). However, revaccination rates have been...
5.
Ogimi C, Xie H, Waghmare A, Jerome K, Leisenring W, Ueda Oshima M, et al.
Bone Marrow Transplant
. 2024 Oct;
59(12):1790.
PMID: 39394376
No abstract available.
6.
Wickline M, Carpenter P, Harris J, Iribarren S, Reding K, Pike K, et al.
Transpl Infect Dis
. 2024 Oct;
26(6):e14388.
PMID: 39373644
Background: Hematopoietic cell transplant (HCT) survivorship care includes recommendations for post-HCT revaccination to restore immunity to vaccine-preventable diseases (VPDs). However, not all survivors agree to be vaccinated. No existing studies...
7.
Wickline M, Carpenter P, Harris J, Iribarren S, Reding K, Pike K, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1221.e1-1221.e13.
PMID: 39303986
Comprehensive survivorship care after hematopoietic cell transplantation (HCT) includes revaccination to restore immunity to vaccine-preventable diseases (VPDs). There is complexity to revaccination in this setting, and revaccination rates are sub-optimal....
8.
Rosen E, Krantz E, McCulloch D, Wilson M, Tverdek F, Kassamali Escobar Z, et al.
Transplant Cell Ther
. 2024 Aug;
30(11):1108.e1-1108.e11.
PMID: 39179107
Recipients of cellular therapies, including hematopoietic cell transplant (HCT) and chimeric antigen receptor T-cell (CART) therapy, are at risk for poor outcomes from coronavirus disease 2019 (COVID-19). There are limited...
9.
Carpenter P, Gooley T, Boiko J, Lee C, Burroughs L, Mehta R, et al.
Blood Adv
. 2024 Aug;
8(22):5829-5837.
PMID: 39167805
Since 2005, there has been a steady decline in chronic graft-versus-host disease (cGVHD) at the Fred Hutchinson Cancer Center. To better understand this phenomenon, we studied the risk of cGVHD...
10.
Hamilton B, Pandya B, Ivanescu C, Elsouda D, Hamadani M, Chen Y, et al.
Blood Adv
. 2024 Aug;
8(19):5091-5099.
PMID: 39167766
The Blood and Marrow Transplant (BMT) Clinical Trials Network conducted a phase 3 randomized trial comparing gilteritinib with placebo after allogeneic hematopoietic cell transplantation (HCT) for FLT3-ITD+ acute myeloid leukemia...